Journey Medical (DERM): microcap biopharma with cash-generating dermatology portfolio and high-upside Emrosi launch. Read ...
Journey Medical Corp (NASDAQ:DERM) is one of the best performing micro cap stocks in 2025. On January 4, Lake Street analyst Thomas Flaten reaffirmed a Buy rating on Journey Medical Corp (NASDAQ:DERM) ...
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermatitis Proposed ...
Journey Medical Corporation misses on earnings expectations. Reported EPS is $-0.16 EPS, expectations were $-0.07. Operator: Ladies and gentlemen, thank you for standing by. Good afternoon, and ...
A U.S. specialty biopharmaceutical company focused on dermatology, with operations centered on commercialization and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results